Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9328293 | Gynecologic Oncology | 2005 | 6 Pages |
Abstract
Chromosome 9 polysomy appears to be a marker of genetic instability that can be used in chemoprevention trials as a surrogate endpoint biomarker. In this randomized trial of 4-HPR, the chromosome 9 polysomy measurements supported the clinical histopathologic reading in a quantitative manner suggesting that 4-HPR at 200 mg/day may have been inhibiting the regression seen in the placebo arm by inducing genetic instability.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Heung Gon Kim, Jose-Miguel Yamal, Xiao-Chun Xu, Wei Hu, Iouri Boiko, Adriana Linares, Anne-Therese Vlastos, E. Neely Atkinson, Anais Malpica, Walter N. Hittelman, Michele Follen,